Insider · CIK 0001763494
Eric M Dube
ceoofficerdirector
Files at TVTX (Travere Therapeutics, Inc.). First filing Jan 23, 2025, latest Sep 17, 2026.
Eric M Dube files SEC Form 4 as CEO and director at TVTX (Travere Therapeutics, Inc.). Since Jan 23, 2025, Eric M Dube has reported 0 open-market buys worth $0 and 12 open-market sells worth $43M, the latest filed on Sep 17, 2026.
A track record needs three past buys with six months of prices behind them; Eric M Dube has 0, so none is measured yet.
The newest scored trade: sold $25M of TVTX on Sep 15, 2026, filed Sep 17, 2026, scored 50 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 8 sells worth $41M.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 12
$0 bought, $43M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TVTX: Travere Therapeutics, Inc.
TVTXOct 9, 2026 · close 52.13
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Travere Therapeutics, Inc. | $25M 400,000 shares | -76% | +175% from low-7% from high | |
| 30Weak | Travere Therapeutics, Inc. | $989k 22,500 shares | -5% | +218% from low-0% from high | |
| 50Moderate | Travere Therapeutics, Inc. | $2.6M 64,000 shares | -13% | +191% from low-3% from high | |
| 35Weak | Travere Therapeutics, Inc. | $1.9M 60,000 shares | -12% | +133% from low-22% from high | |
| 28Weak | Travere Therapeutics, Inc. | $1.8M 60,000 shares | -12% | +125% from low-25% from high | |
| 50Moderate | Travere Therapeutics, Inc. | $3.2M 100,087 shares | -19% | +143% from low-18% from high | |
| 35Weak | Travere Therapeutics, Inc. | $1.8M 60,000 shares | -14% | +118% from low-27% from high | |
| 35Weak | Travere Therapeutics, Inc. | $3.6M 120,000 shares | -23% | +121% from low0% from high | |
| 21Weak | Travere Therapeutics, Inc. | $398k 18,924 shares | -4% | +75% from low-10% from high | |
| 33Weak | Travere Therapeutics, Inc. | $273k 11,375 shares | -3% | - | |
| 50Moderate | Travere Therapeutics, Inc. | $1.0M 50,691 shares | -11% | - | |
| 32Weak | Travere Therapeutics, Inc. | $209k 10,736 shares | -3% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 6, 2026 | TVTX Travere Therapeutics, Inc. | 22,500 0.02% of outstanding | $989k | May 6, 2026 | $6.3M |
| Apr 15, 2026 | TVTX Travere Therapeutics, Inc. | 64,000 0.07% of outstanding | $2.6M | Apr 15, 2026 | $8.7M |
| Apr 1, 2026 | TVTX Travere Therapeutics, Inc. | 60,000 0.07% of outstanding | $1.9M | Apr 1, 2026 | $6.9M |
| Feb 20, 2026 | TVTX Travere Therapeutics, Inc. | 60,000 0.07% of outstanding | $1.8M | Feb 20, 2026 | $5.1M |
| Feb 3, 2026 | TVTX Travere Therapeutics, Inc. | 100,087 0.11% of outstanding | $3.3M | Feb 3, 2026 | $1.8M |
| Jan 27, 2026 | TVTX Travere Therapeutics, Inc. | 51,865 0.06% of outstanding | $1.6M | Jan 27, 2026 | $3.9M |
| Jan 23, 2026 | TVTX Travere Therapeutics, Inc. | 8,135 0.01% of outstanding | $244k | Jan 23, 2026 | $3.6M |
| Oct 29, 2025 | TVTX Travere Therapeutics, Inc. | 27,128 0.03% of outstanding | $817k | Oct 29, 2025 | $2.8M |
| Oct 28, 2025 | TVTX Travere Therapeutics, Inc. | 92,872 0.10% of outstanding | $2.8M | Oct 28, 2025 | none |
| May 5, 2025 | TVTX Travere Therapeutics, Inc. | 18,924 0.02% of outstanding | $398k | May 5, 2025 | $273k |
| Feb 11, 2025 | TVTX Travere Therapeutics, Inc. | 11,375 0.01% of outstanding | $273k | Feb 11, 2025 | $1.2M |
| Feb 3, 2025 | TVTX Travere Therapeutics, Inc. | 50,691 0.06% of outstanding | $1.0M | Feb 3, 2025 | $209k |
| Jan 22, 2025 | TVTX Travere Therapeutics, Inc. | 10,736 0.01% of outstanding | $209k | Jan 22, 2025 | none |
Transactions
The newest 50 of 53 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +95,666 | $23.34 | $2.2M | 528,552 | 26 d ago |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -63,498 | $61.99 | $3.9M | 465,054 | 26 d ago |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -28,796 | $62.66 | $1.8M | 436,258 | 26 d ago |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,102 | $63.64 | $197k | 433,156 | 26 d ago |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -270 | $65.31 | $18k | 432,886 | 26 d ago |
| Sep 16, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +195,841 | $23.34 | $4.6M | 628,727 | 26 d ago |
| Sep 16, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -99,716 | $63.26 | $6.3M | 529,011 | 26 d ago |
| Sep 16, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -96,125 | $63.64 | $6.1M | 432,886 | 26 d ago |
| Sep 17, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +108,493 | $23.34 | $2.5M | 541,379 | 26 d ago |
| Sep 17, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -101,691 | $64.59 | $6.6M | 439,688 | 26 d ago |
| Sep 17, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,802 | $64.95 | $442k | 432,886 | 26 d ago |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -95,666 | $0.00 | $0 | 304,334 | 26 d ago |
| Sep 16, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -195,841 | $0.00 | $0 | 108,493 | 26 d ago |
| Sep 17, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -108,493 | $0.00 | $0 | 0 | 26 d ago |
| May 4, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +22,500 | $0.00 | $0 | 455,386 | May 6, 2026 |
| May 6, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -22,500 | $43.95 | $989k | 432,886 | May 6, 2026 |
| May 4, 2026 | TVTX Travere Therapeutics, Inc. | AGrant or award Performance-based restricted stock unitsderivative10b5-1 | +45,000 | $0.00 | $0 | 45,000 | May 6, 2026 |
| May 4, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Performance-based restricted stock unitsderivative10b5-1 | -22,500 | $0.00 | $0 | 22,500 | May 6, 2026 |
| Apr 13, 2026 | TVTX Travere Therapeutics, Inc. | AGrant or award Common Stock10b5-1 | +64,000 | $0.00 | $0 | 496,886 | Apr 15, 2026 |
| Apr 15, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -56,815 | $41.01 | $2.3M | 440,071 | Apr 15, 2026 |
| Apr 15, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,165 | $41.75 | $299k | 432,906 | Apr 15, 2026 |
| Apr 15, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -20 | $42.66 | $853 | 432,886 | Apr 15, 2026 |
| Apr 1, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +60,000 | $15.46 | $928k | 492,886 | Apr 2, 2026 |
| Apr 1, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -34,902 | $30.55 | $1.1M | 457,984 | Apr 2, 2026 |
| Apr 1, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -25,098 | $31.46 | $790k | 432,886 | Apr 2, 2026 |
| Apr 1, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -60,000 | $0.00 | $0 | 0 | Apr 2, 2026 |
| Feb 20, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +60,000 | $15.46 | $928k | 492,886 | Feb 24, 2026 |
| Feb 20, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -60,000 | $30.10 | $1.8M | 432,886 | Feb 24, 2026 |
| Feb 20, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -60,000 | $0.00 | $0 | 60,000 | Feb 24, 2026 |
| Jan 31, 2026 | TVTX Travere Therapeutics, Inc. | AGrant or award Common Stock10b5-1 | +113,800 | $0.00 | $0 | 532,973 | Feb 3, 2026 |
| Feb 3, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -66,452 | $32.06 | $2.1M | 466,521 | Feb 3, 2026 |
| Feb 3, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -33,635 | $32.70 | $1.1M | 432,886 | Feb 3, 2026 |
| Jan 31, 2026 | TVTX Travere Therapeutics, Inc. | AGrant or award Employee stock option (right to buy)derivative10b5-1 | +303,600 | $0.00 | $0 | 303,600 | Feb 3, 2026 |
| Jan 23, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +8,135 | $15.46 | $126k | 427,308 | Jan 27, 2026 |
| Jan 23, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,135 | $30.01 | $244k | 419,173 | Jan 27, 2026 |
| Jan 27, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +51,865 | $15.46 | $802k | 471,038 | Jan 27, 2026 |
| Jan 27, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -51,865 | $30.10 | $1.6M | 419,173 | Jan 27, 2026 |
| Jan 23, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -8,135 | $0.00 | $0 | 171,865 | Jan 27, 2026 |
| Jan 27, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -51,865 | $0.00 | $0 | 120,000 | Jan 27, 2026 |
| Oct 28, 2025 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +92,872 | $15.46 | $1.4M | 512,045 | Oct 30, 2025 |
| Oct 28, 2025 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -92,872 | $30.38 | $2.8M | 419,173 | Oct 30, 2025 |
| Oct 29, 2025 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +27,128 | $15.46 | $419k | 446,301 | Oct 30, 2025 |
| Oct 29, 2025 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -27,128 | $30.12 | $817k | 419,173 | Oct 30, 2025 |
| Oct 28, 2025 | TVTX Travere Therapeutics, Inc. | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -92,872 | $0.00 | $0 | 207,128 | Oct 30, 2025 |
| Oct 29, 2025 | TVTX Travere Therapeutics, Inc. | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -27,128 | $0.00 | $0 | 180,000 | Oct 30, 2025 |
| May 2, 2025 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +18,924 | - | - | 438,097 | May 5, 2025 |
| May 5, 2025 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -18,924 | $21.05 | $398k | 419,173 | May 5, 2025 |
| May 2, 2025 | TVTX Travere Therapeutics, Inc. | MOption exercise Performance-based restricted stock unitsderivative10b5-1 | -18,924 | $0.00 | $0 | 18,924 | May 5, 2025 |
| Feb 11, 2025 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -11,375 | $24.04 | $273k | 419,173 | Feb 12, 2025 |
| Jan 31, 2025 | TVTX Travere Therapeutics, Inc. | AGrant or award Common Stock10b5-1 | +130,000 | $0.00 | $0 | 481,239 | Feb 4, 2025 |
50 of 53 rows shown.
Questions about Eric M Dube
Answered from the filings on this page, as of the latest one.
Is Eric M Dube buying or selling?
In the last 12 months Eric M Dube reported 0 open-market buys worth $0 and 8 open-market sells worth $41M on SEC Form 4; the latest was sold $25M of TVTX on Sep 15, 2026. Grants, option exercises and tax withholding are not counted.
How did Eric M Dube's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Eric M Dube has 0.
Where does Eric M Dube file Form 4?
Eric M Dube has filed Form 4 at TVTX (Travere Therapeutics, Inc.) as CHIEF EXECUTIVE OFFICER. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.